Search clinical trials for: TMC125-TiDP35-C213

Total 35 results

Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

HIV-1

United States, France, Spain, Portugal, Canada, United Kingdom, South Africa, Argentina, Brazil, Puerto Rico, Thailand, Netherlands, Romania
Janssen Sciences Ireland UC

Active, not recruiting

TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants

HIV Infections | HIV-1

United States, France, Spain, South Africa, Canada, Argentina, Thailand, Brazil, Romania, Panama, Puerto Rico
Janssen R&D Ireland

Completed

A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

Hepatitis C

United States, Australia, France, Ukraine, United Kingdom, Belgium, Germany, Spain, Israel, Portugal, Bulgaria, Netherlands, Canada, New Zealand, Russian Federation, Argentina, Brazil, Puerto Rico, Austria, Poland, Romania, Mexico
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C223: TMC125 in HIV-1 Infected Subjects

HIV Infection
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C211: Trial of TMC125 in HIV-1 Infected Subjects Who Were in a Sponsor Selected TMC125 Trial

HIV Infection
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

HIV

United States, France, Argentina, Chile, Mexico, Costa Rica, Panama, Brazil, Puerto Rico, Thailand
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP2-C188: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Patients on Stable Buprenorphine/Naloxone Maintenance Therapy.

HIV | Pharmacokinetics
Tibotec Pharmaceuticals, Ireland

Completed

An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).

HIV-1

United States, Canada, France, Belgium, Germany, Spain, Argentina, Chile, Panama, Brazil, Puerto Rico, Thailand, Mexico, Australia
Capnia, Inc.

Completed

The Effect of Nasal Carbon Dioxide (CO2) on Nasal Congestion in Subjects With Perennial Allergic Rhinitis

Perennial Allergic Rhinitis

United States
Tibotec Pharmaceuticals, Ireland

Completed

A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study

Human Immunodeficiency Virus Type 1
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

HIV
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.

Fungal Infection | HIV | AIDS
St Stephens Aids Trust

Completed

TMC 125 Blood Levels Study

HIV Infections

United Kingdom
Tibotec Pharmaceuticals, Ireland

Completed

An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.

HIV Infection

United States, Australia, France, United Kingdom, Germany, Spain, Belgium, Portugal, Canada, Argentina, Brazil, Austria, Hungary
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use

HIV Infection
Tibotec Pharmaceuticals, Ireland

Completed

TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients

HIV-Infections
Janssen Korea, Ltd., Korea

Completed

A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence

Acquired Immune Deficiency Syndrome

Korea, Republic of
Janssen R&D Ireland

Completed

TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

HIV Infections | Acquired Immunodeficiency Syndrome

United States, France, Argentina, South Africa, Thailand
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.

HIV
Tibotec Pharmaceuticals, Ireland

Completed

The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs

HIV-1

United States, Belgium, Germany, Taiwan, Spain, Mexico, Turkey, Canada, Netherlands, Denmark, Greece, Sweden, Korea, Republic of, Russian Federation, Puerto Rico, Luxembourg
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients

HIV-1 | Anti-Retroviral Agents
Janssen R&D Ireland

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients

Human Immunodeficiency Virus (HIV) Infection

France, Ukraine, United States, Mexico, Romania, South Africa, Peru, Argentina, Puerto Rico, Russian Federation, Guatemala
Zosano Pharma Corporation

Completed

Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches

Cluster Headache

United States
St Stephens Aids Trust

Completed

Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125

HIV

United Kingdom
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

HIV

United States
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients (SENSE)

Acquired Immunodeficiency Syndrome | HIV Infection | HIV

France, United Kingdom, Germany, Spain, Switzerland, Israel, Russian Federation, Austria, Hungary, Romania, Denmark
Tibotec Pharmaceuticals, Ireland

Completed

TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.

Hepatitis C | HIV

Belgium
Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)

Relapsing Remitting Multiple Sclerosis
Janssen Sciences Ireland UC

Completed

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

HIV-1

United States, South Africa, Ukraine, Kenya, Thailand, India, Romania, Uganda
Janssen Scientific Affairs, LLC

Completed

A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women

HIV Infections | Pregnancy | HIV

United States, Puerto Rico
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).

HIV-1 Infection
University Of Perugia

Unknown

Botulinum A Toxin in the Treatment of Patients With Painful Bladder Syndrome

Painful Bladder Syndrome (PBS)

Italy
Tibotec Pharmaceuticals, Ireland

Completed

TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.

HIV
University Hospital, Bordeaux
University of Bordeaux

Completed

Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation (COVERAGEFrance)

Corona Virus Infection | Sars-CoV2

France
French National Agency for Research on AIDS and...
Merck Sharp & Dohme LLC; Janssen-Cilag Tibotec

Completed

Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses (ANRS139 TRIO)

HIV Infections

France

3

Subscribe